Embed Size (px)
Citation preview
Copyright © 2016 Actelion Pharmaceuticals Ltd
WELCOME TO ACTELION’S AGM 2016
04 May 2016
© 2016 Actelion Pharmaceuticals Ltd
MEETING STRUCTURE
ACTELION’S ANNUAL GENERAL MEETING 2016
Opening Remarks Jean-Pierre Garnier, Chairman of the Board
Business Review 2015 Jean-Paul Clozel, Chief Executive Officer André Muller, Chief Financial Officer
Agenda & Proposals Jean-Pierre Garnier, Chairman of the Board Marian Borovsky, Secretary of the Board of Directors
Annual General Meeting 2016 04 May 2016 2
© 2016 Actelion Pharmaceuticals Ltd
FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING
Annual General Meeting 2016 04 May 2016 3
© 2016 Actelion Pharmaceuticals Ltd
IHR ePAD / YOUR ePAD
Ja Oui Yes
Nein Non
No
Enthaltung Abstention Abstention
Annual General Meeting 2016 04 May 2016 4
© 2016 Actelion Pharmaceuticals Ltd Annual General Meeting 2016 04 May 2016 5
FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING
© 2016 Actelion Pharmaceuticals Ltd
OPENING REMARKS BY THE CHAIRMAN OF THE BOARD
Jean-Pierre Garnier
Annual General Meeting 2016 04 May 2016 6
© 2016 Actelion Pharmaceuticals Ltd
KEY FINANCIAL HIGHLIGHTS 2015
CASH RETURNED TO SHAREHOLDERS
ALMOST CHF 1
BILLION
Core EPS
CHF 6.16 CORE EARNINGS
>CHF 800 MILLION
PRODUCT SALES
>CHF 2 BILLION
Annual General Meeting 2016 04 May 2016 7
© 2016 Actelion Pharmaceuticals Ltd
Jan-15 Apr-15 Jul-15 Oct-15 Jan-16 Apr-16
AGM 2015
ACTELION SHARE PRICE PERFORMANCE
ACTELION
SWISS SMI
Share price development 21% in 2015
Annual General Meeting 2016 04 May 2016 8
© 2016 Actelion Pharmaceuticals Ltd
ALMOST CHF 1 BILLION RETURNED TO SHAREHOLDERS IN 2015
DELIVERING ON OUR STRATEGY CREATES VALUE
CASH RETURNED TO SHAREHOLDERS
358 588
133
927
2012 2013 2014 2015
SHARE PRICE PERFORMANCE
Annual General Meeting 2016 04 May 2016 9
© 2016 Actelion Pharmaceuticals Ltd
OPENING REMARKS BY THE CHAIRMAN OF THE BOARD
Jean-Pierre Garnier
Annual General Meeting 2016 04 May 2016 10
© 2016 Actelion Pharmaceuticals Ltd
OUTSTANDING SUCCESS IN 2015
Jean-Paul Clozel, CEO
Annual General Meeting 2016 04 May 2016 11
© 2016 Actelion Pharmaceuticals Ltd
A SUCCESSFUL YEAR FOR ACTELION
Product success
– Opsumit launch and approval of Uptravi
Pipeline success
– Pipeline progress
Financial success
– Sales of over CHF 2 billion and substantial shareholder return
Annual General Meeting 2016 04 May 2016 12
© 2016 Actelion Pharmaceuticals Ltd
TRANSFORMING OUR PAH PORTFOLIO PAH
Annual General Meeting 2016 04 May 2016 13
© 2016 Actelion Pharmaceuticals Ltd
DIVERSE PORTFOLIO: KEY PROJECTS BEYOND PAH
Ponesimod: Multiple sclerosis
Clazosentan: Reversal of vasospasm post-aSAH
Cadazolid: Clostridium difficile associated diarrhea
Other projects in early stage: Progressing well
Cenerimod: Systemic lupus erythematosus
Annual General Meeting 2016 04 May 2016 14
© 2016 Actelion Pharmaceuticals Ltd
ACTELION 2015 – 2020 CLEAR VISION FOR FUTURE GROWTH
We can create one of the most successful biotech companies in the world!
Annual General Meeting 2016 04 May 2016 15
© 2016 Actelion Pharmaceuticals Ltd
STRONG FINANCIAL PERFORMANCE IN 2015
André C. Muller, CFO
Annual General Meeting 2016 04 May 2016 16
© 2016 Actelion Pharmaceuticals Ltd
1,784
1,956
2,042
2013
2014
2015
PRODUCT SALES FY 2015
2015 PERFORMANCE
11%
Excluding prior year rebate reversals and at constant exchange rates
Annual General Meeting 2016 04 May 2016 17
© 2016 Actelion Pharmaceuticals Ltd
356
369
404
2013
2014
2015
CORE R&D EXPENDITURE FY 2015
INVESTING IN
FUTURE GROWTH
Annual General Meeting 2016 04 May 2016 18
© 2016 Actelion Pharmaceuticals Ltd
619
743
814
2013
2014
2015
CORE EARNINGS FY 2015
2015 PERFORMANCE
25%
Excluding prior year rebate reversals and at constant exchange rates
Annual General Meeting 2016 04 May 2016 19
© 2016 Actelion Pharmaceuticals Ltd
4.41
5.58
6.16
2013
2014
2015
CORE EARNINGS PER SHARE FY 2015
2015 PERFORMANCE
26%
Annual General Meeting 2016 04 May 2016 20
Excluding prior year rebate reversals and at constant exchange rates
© 2016 Actelion Pharmaceuticals Ltd
CASH POSITION AND CASH FLOW FY 2015
Annual General Meeting 2016 04 May 2016 21
1,205
609 609 406 405
658 927
327 79 282
Gross cash31 Dec 14
Operatingcash flow
Cash returned toshareholders
1st line sharepurchase
ESOPproceeds
Bond repayment,other itmes
Net cash31 December 15
© 2016 Actelion Pharmaceuticals Ltd
Q1 2016 – FINANCIAL OVERVIEW
Annual General Meeting 2016 04 May 2016 22
Variance
Q1 2015 Q1 2016 CHF CER
Product sales CHF million
515 589 14% 11%
Core operating income CHF million
218 249 14% 8%
Core diluted EPS CHF
1.61 1.98 23% 17%
Operating income CHF million
190 208 10% 3%
US GAAP diluted EPS CHF
1.38 1.64 19% 11%
© 2016 Actelion Pharmaceuticals Ltd
AT CONSTANT EXCHANGE RATES
2016 FINANCIAL GUIDANCE
High single-digit percentage core operating income growth, at constant exchange rates and barring unforeseen events
Annual General Meeting 2016 04 May 2016 23
© 2016 Actelion Pharmaceuticals Ltd
CONCLUDING REMARKS BY THE CHAIRMAN OF THE BOARD
Annual General Meeting 2016 04 May 2016 24
